iCAD (NASDAQ:ICAD) Downgraded by StockNews.com to Sell

iCAD (NASDAQ:ICAD) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday.

iCAD Stock Down 0.4 %

iCAD stock traded down $0.01 during midday trading on Tuesday, reaching $2.32. The stock had a trading volume of 199,432 shares, compared to its average volume of 247,663. iCAD has a 12 month low of $1.18 and a 12 month high of $3.78. The firm’s 50-day moving average price is $2.63 and its 200 day moving average price is $2.05. The firm has a market capitalization of $61.57 million, a PE ratio of -17.85 and a beta of 1.95.

Institutional Investors Weigh In On iCAD

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Granahan Investment Management LLC bought a new stake in shares of iCAD during the fourth quarter valued at about $96,000. Integrated Wealth Concepts LLC bought a new stake in shares of iCAD during the fourth quarter valued at about $92,000. Wells Fargo & Company MN increased its position in shares of iCAD by 51.3% during the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after buying an additional 13,402 shares during the period. Perritt Capital Management Inc increased its position in shares of iCAD by 1.9% during the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company’s stock valued at $346,000 after buying an additional 3,600 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of iCAD by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company’s stock valued at $506,000 after buying an additional 17,059 shares during the period. 24.61% of the stock is currently owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.